BIC/FTC/TAF 单片方案真实世界临床疗效和安全性研究.

Objective To analyze the efficacy and safety of the three-in-one single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide（BIC/FTC/TAF） in AIDS patients. Methods Newly treated patients who received a single tablet combination（BIC/FTC/TAF） between February 1，2022 and June 1，2022（the initial treatment group） and those who underwent treatment（ the treated group） were included. The virological， immunological and biochemical indexes were statistically analyzed by means of prospective observational study. Results 249 patients were included at baseline, with 220 in the treated group and 29 in the newly treated group. At 48 weeks， the analysis showed that the virus suppression rate was 93.10% for the newly treated group and 98.55% for the treated group. Compared to the baseline, both groups showed increased CD4+ T lymphocyte counts and CD4+ /CD8+ T cell ratios after 48 weeks of treatment（P < 0.001）. There were also significant increases in blood triglycerides, total cholesterol, total bilirubin, and blood creatinine compared to the baseline（P < 0.05）. Aspartate aminotransferase and alanine aminotransferase decreased compared to the baseline， with all differences being statistically significant except for alanine aminotransferase in the newly treated group（P > 0.05）. Additionally，the estimated glomerular filtration rate based on blood creatinine improved in the newly treated group compared to the baseline（P < 0.001），while there were no significant changes in the treated group. Conclusion BIC/FTC/TAF can effectively inhibit virus replication，improve the immune function of patients, and has good safety. Bic /FTC/TAF can be one of the preferred treatment options for some specific clinical populations. [ABSTRACT FROM AUTHOR]